

Efficacy and Safety of Non-Corticosteroid Immunosuppressants in Juvenile Myasthenia Gravis: A systematic review and meta analysis

INPLASY202530109  
doi: 10.37766/inplasy2025.3.0109  
Received: 25 March 2025  
Published: 25 March 2025

Zhong, XL; Luo, R.

**Corresponding author:**  
Xiaoling Zhong

shirlie1995@163.com

**Author Affiliation:**  
West China Second University  
Hospital, Sichuan University.

ADMINISTRATIVE INFORMATION

**Support** - None.  
**Review Stage at time of this submission** - Piloting of the study selection process.  
**Conflicts of interest** - None declared.  
**INPLASY registration number:** INPLASY202530109  
**Amendments** - This protocol was registered with the International Platform of Registered Systematic Review and Meta-Analysis Protocols (INPLASY) on 25 March 2025 and was last updated on 25 March 2025.

INTRODUCTION

**Review question / Objective** To analyze the efficacy and safety of non-corticosteroid immunosuppressants in Juvenile myasthenia gravis.

**Condition being studied** For Juvenile myasthenia gravis who were <18 years at the time of assent/consent; confirmed MG diagnosis with positive serologic test for anti-AChR antibodies; refractory MG.

METHODS

**Participant or population** For Juvenile myasthenia gravis who were <18 years at the time of assent/consent; confirmed MG diagnosis with positive serologic test for anti-AChR antibodies; refractory MG.

**Intervention** Non-Corticosteroid Immunosuppressants.

**Comparator** Corticosteroid Immunosuppressants and pyridostiamine.

**Study designs to be included** Prospective studies.

**Eligibility criteria** inclusion: definitive treatment and outcomes.  
Exclusion: abstracts, no sufficient data.

**Information sources** Electronic databases.

**Main outcome(s)** a. Myasthenia Gravis Activities of Daily Living (MG-ADL) score; b. Quantitative Myasthenia Gravis (QMG) score; c. Myasthenia Gravis Composite (MGC) score; d. adverse effects (AEs).

**Quality assessment / Risk of bias analysis** Cochrane ROB 2.0 and ROBINS-I tools.

**Strategy of data synthesis** Quantative and qualitative analysis.

---

**Subgroup analysis** Stata software and Revman 5.4 software to conduct subgroup analysis.

**Sensitivity analysis** Stata software to conduct sensitivity analysis.

**Country(ies) involved** China.

**Keywords** Juvenile Myasthenia Gravis; systematic review; Non-Corticosteroid Immunosuppressants.

**Contributions of each author**

Author 1 - Xiaoling Zhong.

Author 2 - Rong Luo.